ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MBX / news
VCRE (49) VRDN (45) PGEN (33) ZLAB (28) ⌘ Pro Terminal →

Why MBX Stock dropped -2.63% Today — RQD Quant Desk Flash

$54.40 -2.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $54.04

MBX Biosciences Inc. (MBX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.69B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MBX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, MBX Biosciences Inc. (NASDAQ: MBX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $54.40 (-2.63% 1D, market cap $2.69B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MBX compare to VCRE and VRDN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -26.4%. By comparison, VCRE (Vicore Pharma Holding AB) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.76B) and VRDN (Viridian Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.79B). Among the 5-stock peer group, MBX leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MBX?
▼

Per MBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001776111), MBX Biosciences Inc. generated $274.6M in revenue (+43.8% YoY), -$87.0M in net income, and -$81.9M in free cash flow against $385.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $54.04 (-0.66%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (11)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$76 Bull$50 Base$39 Bear
📬 FREE MBX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY MBX SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
32
Grade E$49.00+9.2% Next Q
Q2 (-2Q)
35
Grade E$53.50-1% Next Q
Q3 (-1Q)
37
Grade E$52.97+2.7% Next Q
Current
40
Grade D-$54.40-7.4% Hist 90D α
Trajectory: E (32) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MBX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MBX currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($57.37) and Max Pain ($57.12) forces dealer call-delta covering toward $76.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MBX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MBX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why MBX Stock dropped -2.63% Today — RQD Quant Desk Flash

MBX Biosciences Inc. (MBX) dropped -2.63% to $54.40, trading at 65% of its 52-week range ($20.21 – $72.64). Stretched risk/reward at current multiples (-26% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 65% of its 52-week range ($20.21 – $72.64) with RSI-14 at 53.6 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $54.40 (no active unusual options sweep snapshot on file).
  • ▸Primary SEC / Cross-Feed Trigger: MBX Exhibits 2.96x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live MBX Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBX)

  • ✓Walkthrough of MBX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MBX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +84.78%⚡ TESTING RESISTANCE
2026-11-03O $54.54H $55.87L $54.40C $54.40VOL 667.3K
RES: $56.60SUP: $47.01SMA50: $57.37SMA200: $45.72
$75.95$62.23$48.50$34.78$21.05RES $56.60SUP $47.01$54.402026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MBX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MBX Butterfly Map → + Track MBX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +43.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MBX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MBX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MBX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBX)

Health Care Rank #453 of 1015 ⚔️ VCRE vs MBX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MBX vs. VCRE, VRDN, PGEN, ZLAB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, MBX Biosciences Inc. (MBX) ranks #453 by composite RQD confidence (40/100, grade D-) and #215 by equity capitalization ($2.69B). Within this direct 5-issuer industry benchmark cohort, MBX leads on earnings valuation at N/A trailing P/E, while MBX leads on capital efficiency and profitability with -26.4% ROIC and — gross margin. VCRE currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with MBX at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MBX ACTIVE
MBX Biosciences Inc.
D- 40/100 — — -26.4% -2.63% $2.69B Benchmark Subject
VCRE
Vicore Pharma Holding AB
D 49/100 — — — -2.14% $2.76B /vcre-vs-mbx →
VRDN
Viridian Therapeutics Inc.
D 45/100 — — -35.0% +2.55% $2.79B /vrdn-vs-mbx →
PGEN
Precigen Inc.
E 33/100 — — -35.0% -25.94% $2.48B /pgen-vs-mbx →
ZLAB
Zai Lab Limited
E 28/100 — 58.3% -35.0% -1.83% $2.48B /zlab-vs-mbx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001776111 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MBX Biosciences Inc. (MBX) reported GAAP revenue of $274.6M (+43.8% vs. FY2024 revenue of $190.9M , and +177.7% cumulative change since FY2023) , GAAP net income of -$87.0M, operating cash flow of -$79.9M, and free cash flow of -$81.9M (-47.4% YoY). On the balance sheet, MBX closed FY2025 with $385.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $274.6M -$87.0M -$79.9M -$81.9M $385.1M —
FY2024 (FY) 2024-12-31 $190.9M -$61.9M -$54.7M -$55.6M $268.5M —
FY2023 (FY) 2023-12-31 $98.9M -$32.6M -$32.0M -$32.0M — —

3. MBX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, MBX Biosciences Inc. (NASDAQ: MBX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $54.40 (-2.63% 1D, market cap $2.69B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does MBX compare to VCRE and VRDN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -26.4%. By comparison, VCRE (Vicore Pharma Holding AB) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.76B) and VRDN (Viridian Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.79B). Among the 5-stock peer group, MBX leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MBX?

Per MBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001776111), MBX Biosciences Inc. generated $274.6M in revenue (+43.8% YoY), -$87.0M in net income, and -$81.9M in free cash flow against $385.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MBX trading relative to its 50-day, 200-day, and 52-week technical levels?

MBX last traded at $54.40 (-2.63% on volume of 326,440 shares), positioning the stock -5.18% below its 50-day simple moving average ($57.37) and +18.99% above its 200-day simple moving average ($45.72). Across its 52-week range of $20.21 to $72.64, MBX sits at the 65.2% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($47.60 to $61.20).

Direct Sub-Reports: MBX RQD Cockpit MBX 12M Forecast MBX Earnings & Move MBX Dividends & DRIP MBX Insiders & 13F MBX Whale Options MBX Profit Sankey MBX News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MBX — MBX Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

MBX Biosciences Inc. (MBX) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $54.40 (-2.63% 1D, market capitalization $2.69B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -26.4%, gross margin of —, operating margin of —, and free cash flow yield of -3.12%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

MBX Biosciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The source does not describe its products, customers, or revenue model. Reported revenue is — for each period provided (), so the source does not show a revenue-generating commercial operation during those years.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), MBX Biosciences Inc. (MBX) reported $274.6M in annual revenue (up from $190.9M in FY2024, +43.8% YoY) and -$87.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($98.9M revenue, -$32.6M net income) through FY2025, MBX scaled operating cash flow to -$79.9M and free cash flow to -$81.9M, backed by $385.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.12% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $20.21 – $72.64 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MBX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can MBX sustain or expand its — operating margin and -26.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $274.6M and free cash flow of -$81.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MBX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MBX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MBX Biosciences Inc. (MBX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MBX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MBX Bull vs. Bear Conversation Board — What's Your Call at $54.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MBX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MBX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $72.63 (+30.0%)
📌 Pinned Debate

Recent news reports a 257% share price jump and a $83.89 average price target, suggesting positive market attention and analyst expecta

Here is why I am bullish on MBX here at $55.87: Recent news reports a 257% share price jump and a $83.89 average price target, suggesting positive market attention and analyst expectations.. Compare MBX's 0.0% operating margin and -26.4% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $53.08 are getting bought.

SectorRotator 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $45.25 (-19.0%)
Spot @ $55.87

The RQD rating of 39/D- reflects negative ROIC of -26.4%, negative FCF yield of -3.12%, zero revenue, and a Piotroski F-Score of 2/9.

Careful chasing MBX at $55.87. The RQD rating of 39/D- reflects negative ROIC of -26.4%, negative FCF yield of -3.12%, zero revenue, and a Piotroski F-Score of 2/9.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $45.25 on multiple compression.

LIVE TAPE